论文部分内容阅读
目的分析沈阳市2000-2015年宫颈癌的死亡情况及变化趋势。为沈阳市宫颈癌的防治工作提供依据。方法收集、整理沈阳市2000-2015年宫颈癌的死亡数据,计算各年粗死亡率、构成比及标化率等,采用Joinpoint模型对死亡率进行趋势性分析。结果沈阳市2000-2015年宫颈癌死亡病例1 172例,粗死亡率为4.11/10万,中标率为2.78/10万,世标率为2.57/10万,16年来死亡率呈上升趋势,世标率APC为4.72%(95%CI:3.15%~6.31%);死亡病例主要集中在40~59岁年龄组,占死亡人数的54.10%;中年组(35~59岁组)宫颈癌的死亡率呈持续上升趋势,16年间APC为7.58%(95%CI:5.14%~10.08%);老年组(≥60岁)的宫颈癌死亡率在2000-2008年间呈下降趋势,APC为-7.25%(95%CI:-12.50%~-1.68%),2008-2015年呈上升趋势,APC为9.26%(95%CI:2.44%~16.53%)。结论沈阳市宫颈癌死亡率呈逐年上升的趋势,死亡病例多集中在中年女性人群。应将宫颈癌的筛查年龄提前,并对宫颈癌患者进行积极、规范治疗,以降低宫颈癌的死亡率。
Objective To analyze the death and change of cervical cancer in Shenyang from 2000 to 2015. Shenyang City for the prevention and treatment of cervical cancer provide the basis. Methods The death data of cervical cancer from 2000 to 2015 in Shenyang were collected, and the crude mortality rate, composition ratio and standardization rate of each year were calculated, and the trend of mortality was analyzed by Joinpoint model. Results There were 1 172 cases of cervical cancer death in 2000-2015 in Shenyang City. The crude death rate was 4.11 / 100,000, the successful rate was 2.78 / 100,000 and the world standard rate was 2.57 / 100,000. The mortality rate in 16 years showed an upward trend. The rates of APC were 4.72% (95% CI: 3.15% ~ 6.31%). The deaths were mainly in the age group of 40-59 years, accounting for 54.10% of the deaths; in the middle-aged group (35-59 years) The mortality rate showed an upward trend. The 16-year APC was 7.58% (95% CI: 5.14% -10.08%). The mortality rate of cervical cancer in the elderly group (≥60 years old) decreased from 2000 to 2008 with an APC of -7.25 % (95% CI: -12.50% ~ -1.68%), with a rising trend from 2008 to 2015 with an APC of 9.26% (95% CI: 2.44% ~ 16.53%). Conclusion The mortality rate of cervical cancer in Shenyang shows an increasing trend year by year. The death cases are mostly concentrated in the middle-aged female population. Cervical cancer screening should be advanced age, and cervical cancer patients active and standardized treatment to reduce cervical cancer mortality.